244 related articles for article (PubMed ID: 2079381)
21. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
[TBL] [Abstract][Full Text] [Related]
22. Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
Landmark J; Merskey H; Cernovsky ZZ
Can J Psychiatry; 1994 May; 39(4):219-22. PubMed ID: 8044729
[TBL] [Abstract][Full Text] [Related]
23. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
[TBL] [Abstract][Full Text] [Related]
24. [Clinical observations of treatment with Lyorodin-depot (Jenapharm)].
Pirozynski T; Chiriţă V; Cosmovici N; Offenberg C; Chiriac ME; Marinescu V; Cojocaru M; Berlescu M; Mungiu A
Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):501-9. PubMed ID: 2700035
[TBL] [Abstract][Full Text] [Related]
25. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].
Woggon B; Dick P; Fleischhauer HJ; Gmür M; Gruber G; Angst J; Heimann H
Int Pharmacopsychiatry; 1977; 12(4):193-209. PubMed ID: 22515
[TBL] [Abstract][Full Text] [Related]
27. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
[TBL] [Abstract][Full Text] [Related]
28. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.
Wistedt B; Palmstierna T
J Clin Psychiatry; 1983 Oct; 44(10):369-71. PubMed ID: 6643398
[TBL] [Abstract][Full Text] [Related]
29. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
Jain RC; Ananth JV; Lehmann HE; Ban TA
Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
[No Abstract] [Full Text] [Related]
30. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
Walker CA
Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
[TBL] [Abstract][Full Text] [Related]
31. [Social integration of long-term paraphrenic patients with low-dose depot neuroleptic medication].
Lesch OM; Dietzel-Rogan M; Musalek M; Rajna P; Rustembegovich A; Schjerve M; Walter H
Psychiatr Prax; 1985 Mar; 12(2):63-8. PubMed ID: 3887443
[TBL] [Abstract][Full Text] [Related]
32. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
Bransgrove LL; Kelly MW
Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
[TBL] [Abstract][Full Text] [Related]
33. [Long-term clinical experience with clozapine].
Gelly F; Chambon O; Marie-Cardine M
Encephale; 1997; 23(5):385-96. PubMed ID: 9453932
[TBL] [Abstract][Full Text] [Related]
34. Depot fluphenazine: risk/benefit ratio.
Glazer WM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):28-35. PubMed ID: 6370986
[TBL] [Abstract][Full Text] [Related]
35. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
Cookson JC; Kennedy NM; Gribbon D
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
[TBL] [Abstract][Full Text] [Related]
36. A comparative trail of fluphenazine decanoate and flupenthixol decanoate.
Haslam MT; Bromham BM; Schiff AA
Acta Psychiatr Scand; 1975 Feb; 51(2):92-100. PubMed ID: 1091124
[TBL] [Abstract][Full Text] [Related]
37. Early hospital experience with fluphenazine decanoate.
Small JG; Kellams J
Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
[TBL] [Abstract][Full Text] [Related]
38. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
[TBL] [Abstract][Full Text] [Related]
39. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
Knights A; Okasha MS; Salih MA; Hirsch SR
Br J Psychiatry; 1979 Dec; 135():515-23. PubMed ID: 394794
[TBL] [Abstract][Full Text] [Related]
40. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
